Metabolic signature biomarkers for predicting the recurrence of urological cancers
This article critically reviews for the first time, to our knowledge, the promise of metabolomics-based approaches to identify metabolic signatures as candidate prognostic biomarkers to predict recurrences at the time of surgery in prostate cancer (PCa), bladder cancer (BCa), and renal cell carcinoma (RCC). Dysregulations in the levels of several tumoral, circulating, and excreted metabolites have been reported in PCa patients experiencing recurrence within 1.5 to 8 years of follow-up. The combination of these metabolic biomarkers with clinical parameters (e.g., pathological T stage, Gleason score) has shown great potential to improve the predictive ability of PCa recurrence. In contrast, predictive biomarkers of recurrence in BCa and RCC have been poorly explored. Overall, this review highlights the great potential of metabolomics in discovering prognostic biomarkers for a more accurate patient risk stratification in urological cancers.PMID:37690663 | DOI:10.1016/j.cca.2023.117553
Source: International Journal of Clinical Chemistry - Category: Chemistry Authors: Filipa Amaro M árcia Carvalho Maria de Lourdes Bastos Paula Guedes de Pinho Joana Pinto Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemistry | Kidney Cancer | Prostate Cancer | Renal Cell Carcinoma | Urology & Nephrology